Ge Healthcare A/S

The Company's principal activities The main activity of the Company is to trade in research- and pharmaceutical products, mainly sales of specialized products for the diagnosis of diseases. These include radiological contrast agents (X-ray / computed tomography or magnetic camera examination), ultrasound contrast agent for cardiology, and radiopharmaceuticals for diagnosis (SPECT, PET) and treatment. The Company is a distributor and part of the Pharmaceutical Diagnostics (PDx) business unit of GE HealthCare Technologies Inc. Development in activities and the financial situation The Company's Income Statement of the financial year 1 January 2023 - 31 December 2023 shows a result of DKK 1.389.898 and the Balance Sheet at 31 December 2023 a balance sheet total of DKK 30.790.573 and an equity of DKK 14.354.281. After a 2022 where shortage of iodine as raw material for our x-ray portfolio impacted our ability to fully serve customer in parts of the year, the ability to serve our customers in full have improved back to historic service levels, during 2023. The sales and marketing organization has continued to focus on defined products, and maintained its position as market leader. GE Healthcare will expand the product portfolio in the future. The company develops new drugs primarily in the field of PET (molecular imaging) and new contrast agents for magnetic resonance imaging. GE Healthcare also collaborates with other companies, in order to be able to offer and distribute a complete product portfolio. Uncertainty and risks that the company is affected by are the continued increased price development of the raw material iodine and the general higher inflation rate seen for commodities such as energy and transport. Initiative to continue sharing the increased cost with our customer in terms of price increases remain a key priority. The Company’s new ultimate parent is GE HealthCare Technologies Inc, replacing General Electric Company (GE). GE HealthCare Holding LLC was formed as a Delaware limited liability corporation on 16 May 2022 for the purpose of receiving all net assets of GE HealthCare. On 29 December 2022, GE HealthCare Holding LLC converted into a Delaware corporation and was renamed GE HealthCare Technologies Inc. The separation was completed on 3 January 2023 through a distribution of approximately 80.1% of the common stock of GE HealthCare Technologies Inc to holders of record of GE's common stock as of the close of business on 16 December 2022, and GE HealthCare Technologies Inc became an independent public company, listed under the symbol “GEHC” on the Nasdaq Stock Market LLC. The company's first day of trading on Nasdaq was on 4 January 2023 GE HealthCare Technologies Inc (88-2515116),is registered in Delaware, with principal address at 500 W. Monroe Street, Chicago, Illinois 60661, US. As a result of the spin-off, On 3 January 2023, GE Healthcare A/S, GE Healthcare Danmark A/S and BK Medical ApS exited the national Danish joint taxation group formed with other Danish entities in the GE group. Starting from 4 January 2023, GE Healthcare Danmark A/S (CVR 26527791) is the new administration company for the GE Healthcare joint taxation group of legal entities in Denmark. Post financial year events After the end of the financial year, no events have occurred which may change the financial position of the entity substantially.

Development in activities and the financial situation The Company's Income Statement of the financial year 1 January 2023 - 31 December 2023 shows a result of DKK 1.389.898 and the Balance Sheet at 31 December 2023 a balance sheet total of DKK 30.790.573 and an equity of DKK 14.354.281. After a 2022 where shortage of iodine as raw material for our x-ray portfolio impacted our ability to fully serve customer in parts of the year, the ability to serve our customers in full have improved back to historic service levels, during 2023. The sales and marketing organization has continued to focus on defined products, and maintained its position as market leader. GE Healthcare will expand the product portfolio in the future. The company develops new drugs primarily in the field of PET (molecular imaging) and new contrast agents for magnetic resonance imaging. GE Healthcare also collaborates with other companies, in order to be able to offer and distribute a complete product portfolio. Uncertainty and risks that the company is affected by are the continued increased price development of the raw material iodine and the general higher inflation rate seen for commodities such as energy and transport. Initiative to continue sharing the increased cost with our customer in terms of price increases remain a key priority. The Company’s new ultimate parent is GE HealthCare Technologies Inc, replacing General Electric Company (GE). GE HealthCare Holding LLC was formed as a Delaware limited liability corporation on 16 May 2022 for the purpose of receiving all net assets of GE HealthCare. On 29 December 2022, GE HealthCare Holding LLC converted into a Delaware corporation and was renamed GE HealthCare Technologies Inc. The separation was completed on 3 January 2023 through a distribution of approximately 80.1% of the common stock of GE HealthCare Technologies Inc to holders of record of GE's common stock as of the close of business on 16 December 2022, and GE HealthCare Technologies Inc became an independent public company, listed under the symbol “GEHC” on the Nasdaq Stock Market LLC. The company's first day of trading on Nasdaq was on 4 January 2023 GE HealthCare Technologies Inc (88-2515116),is registered in Delaware, with principal address at 500 W. Monroe Street, Chicago, Illinois 60661, US. As a result of the spin-off, On 3 January 2023, GE Healthcare A/S, GE Healthcare Danmark A/S and BK Medical ApS exited the national Danish joint taxation group formed with other Danish entities in the GE group. Starting from 4 January 2023, GE Healthcare Danmark A/S (CVR 26527791) is the new administration company for the GE Healthcare joint taxation group of legal entities in Denmark.